firmagon
ferring pharmaceuticals a/s - degarelix - prostatas audzēji - endokrīnā terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
jevtana
sanofi winthrop industrie - cabazitaxel - prostatas audzēji - antineoplastiski līdzekļi - jevtana kombinācijā ar prednizonu vai prednizolonu ir indicēts pacientu ārstēšanai ar hormonālo refraktoru metastātisku prostatas vēzi, kas iepriekš tika ārstēti ar docetakselu saturošu shēmu.
xtandi
astellas pharma europe b.v. - enzalutamide - prostatas audzēji - endokrīnā terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
cabazitaxel teva
teva b.v. - cabazitaxel - prostatas audzēji - antineoplastiski līdzekļi - Ārstēšana prostatas vēža.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatas audzēji - citi hormonu antagonisti un tiem līdzīgas vielas - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
tadustix 0,5 mg/0,4 mg cietās kapsulas
krka, d.d., novo mesto, slovenia - dutasteridum, tamsulosini hydrochloridum - kapsula, cietā - 0,5 mg/0,4 mg
unisol 0,5 mg/0,4 mg cietās kapsulas
exeltis baltics uab, lithuania - dutasteridum, tamsulosini hydrochloridum - kapsula, cietā - 0,5 mg/0,4 mg
dutasteride/tamsulosin viatris 0,5 mg/0,4 mg cietās kapsulas
viatris limited, ireland - dutasteridum, tamsulosini hydrochloridum - kapsula, cietā - 0,5 mg/0,4 mg
dutasteride/tamsulosin teva 0,5 mg/0,4 mg cietās kapsulas
teva b.v., netherlands - dutasteridum, tamsulosini hydrochloridum - kapsula, cietā - 0,5 mg/0,4 mg
colcaps 500 mg/100 mg/6,1 mg cietās kapsulas
richard bittner ag, austria - paracetamolum, guaifenesinum, phenylephrini hydrochloridum - kapsula, cietā - 500 mg/100 mg/6,1 mg